Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.58 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7015663 | 0.81 | KEAP1 (0.40) | KEAP1NFE2L2LMNAMAPT | |
| SCHEMBL10501891 | 0.81 | KEAP1 (0.66) | KEAP1NFE2L2CTNNB1TCF7L2ALPL | |
| SCHEMBL9187616 | 0.80 | POLB (0.45) | LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL6170105 | 0.78 | KEAP1 (0.47) | KEAP1NFE2L2CTNNB1TCF7L2MAPT | |
| SCHEMBL10806450 | 0.77 | CES2 (0.33) | KEAP1NFE2L2MDM2AKR1C3AKR1C2 | |
| SCHEMBL9686323 | 0.77 | KEAP1 (0.51) | KEAP1NFE2L2LMNAKDM4EALPL | |
| SCHEMBL5158128 | 0.75 | SLC6A12 (0.37) | KEAP1NFE2L2AKR1C3AKR1C2KDM4E | |
| SCHEMBL29744459 | 0.75 | KEAP1 (1.00) | KEAP1NFE2L2CTNNB1TCF7L2LMNA | |
| SCHEMBL113812 | 0.75 | KEAP1 (1.00) | KEAP1NFE2L2CTNNB1TCF7L2LMNA | |
| SCHEMBL1345064 | 0.74 | CES2 (0.36) | AKR1C3AKR1C2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340746-B1 | Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives | SALTIGO GMBH (DE) | 2007-02-28 | — | — | EP | disclosed |
| EP-1341781-B1 | ANTIMICROBIAL QUINOLONES | PROCTER & GAMBLE (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6900224-B2 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040038975-A1 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY | 2004-02-26 | — | — | US | disclosed |
| US-20040029882-A1 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE CO. | 2004-02-12 | — | — | US | disclosed |
| US-6645981-B2 | For therapy of microbial infection | THE PROCTER & GAMBLE COMPANY | 2003-11-11 | — | — | US | disclosed |
| EP-1340746-A1 | Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives | BAYER AG (DE) | 2003-09-03 | — | — | EP | disclosed |
| US-20030008894-A1 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038975-A1 | Antimicrobial quinolones, their compositions and uses | QARS1, NQO2, Q6ZSR9 | KEAP1 1044/4885NFE2L2 1732/4885CTNNB1 2807/4885 |
| US-20030008894-A1 | Antimicrobial quinolones, their compositions and uses | QARS1, NQO2, Q6ZSR9 | KEAP1 1044/4885NFE2L2 1732/4885CTNNB1 2807/4885 |
| US-20040029882-A1 | Antimicrobial quinolones, their compositions and uses | QARS1, NQO2, Q6ZSR9 | KEAP1 1044/4885NFE2L2 1732/4885CTNNB1 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.